These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1260 related articles for article (PubMed ID: 26994877)
1. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877 [TBL] [Abstract][Full Text] [Related]
2. Multifunctional Bioconjugate for Cancer Cell-Targeted Theranostics. Du W; Yuan Y; Wang L; Cui Y; Wang H; Xu H; Liang G Bioconjug Chem; 2015 Dec; 26(12):2571-8. PubMed ID: 26580576 [TBL] [Abstract][Full Text] [Related]
3. A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo. Taghdisi SM; Danesh NM; Ramezani M; Yazdian-Robati R; Abnous K Mol Pharm; 2018 May; 15(5):1972-1978. PubMed ID: 29669200 [TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance. Zeng X; Morgenstern R; Nyström AM Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875 [TBL] [Abstract][Full Text] [Related]
5. Improving Chemotherapy Effectiveness: Utilizing CuS Nanoparticles Coated with AS1411 Aptamer and Chitosan for Targeted Delivery of Doxorubicin to Cancerous Cells. Imanimoghadam M; Yaghoobi E; Alizadeh F; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM J Pharm Sci; 2024 Jul; 113(7):1865-1873. PubMed ID: 38342338 [TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794 [TBL] [Abstract][Full Text] [Related]
7. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells. Joshi M; Choi JS; Park JW; Doh KO J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295 [TBL] [Abstract][Full Text] [Related]
8. Targeted co-delivery of FOXM1 aptamer and DOX by nucleolin aptamer-functionalized pH-responsive biocompatible nanodelivery system to enhance therapeutic efficacy against breast cancer: in vitro and in vivo. Masoudi M; Taghdisi SM; Hashemitabar G; Abnous K Drug Deliv Transl Res; 2024 Jun; 14(6):1535-1550. PubMed ID: 38161196 [TBL] [Abstract][Full Text] [Related]
9. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Pi F; Zhang H; Li H; Thiviyanathan V; Gorenstein DG; Sood AK; Guo P Nanomedicine; 2017 Apr; 13(3):1183-1193. PubMed ID: 27890659 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692 [TBL] [Abstract][Full Text] [Related]
11. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899 [TBL] [Abstract][Full Text] [Related]
12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
13. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance. Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018 [TBL] [Abstract][Full Text] [Related]
14. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer. Li X; Wu X; Yang H; Li L; Ye Z; Rao Y Biomed Pharmacother; 2019 Sep; 117():109072. PubMed ID: 31202169 [TBL] [Abstract][Full Text] [Related]
15. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery. Liu X; Wu L; Wang L; Jiang W Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244 [TBL] [Abstract][Full Text] [Related]
16. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related]
17. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702 [TBL] [Abstract][Full Text] [Related]
18. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704 [TBL] [Abstract][Full Text] [Related]
19. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
20. Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery. Xu L; He XY; Liu BY; Xu C; Ai SL; Zhuo RX; Cheng SX Colloids Surf B Biointerfaces; 2018 Nov; 171():24-30. PubMed ID: 30005287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]